More precise biomarkers of endocrine therapy response
are needed in breast cancer. Skliris and colleagues
observed that estrogen receptor-α (ERα) phosphorylation
on the serine-282 residue is predictive of a good clinical
outcome and that phosphorylation on threonine-311 is
predictive of a poor clinical outcome in a tamoxifen
treated cohort. This suggests an improvement over the
current ERα status system could be developed based on
which ERα residues are phosphorylated in a given tumour. Skliris
et al. (2010)
Endocrine-Related Cancer 17, 589-597.
DOI: 10.1677/ERC-10-0030